Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
NCT ID: NCT04080544
Last Updated: 2023-09-28
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
125 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-01-15
Study Completion Date
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators will conduct tau positron emission tomography (PET) scans on 125 adults using the radiopharmaceutical Flortaucipir F18 (\[18F\]AV-1451). This will allow the investigators to determine tau deposition across adults of different ages and assess the relationship of current tau burden to cognitive function and amyloid deposition collected over the previous 10-year interval.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects
NCT04474405
Alzheimer Disease
COMPLETED
EARLY_PHASE1
Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
NCT04468347
Alzheimer Disease
Mild Cognitive Impairment
COMPLETED
PHASE1
Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants
NCT02792179
Alzheimer's Disease
COMPLETED
PHASE1
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
NCT03901105
Alzheimer Disease
COMPLETED
PHASE3
Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)
NCT00857506
Alzheimer's Disease
Mild Cognitive Impairment
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Alzheimer's disease (AD) is a highly prevalent disorder of dementia in older adults. AD neuropathology is marked by the presence of amyloid plaques and tau neurofibrillary tangles. Autopsy studies, as well as magnetic resonance imaging (MRI) studies in living persons, have established that the neurodegenerative changes in AD begin in medial temporal lobe structures and later progress to adjacent temporal, parietal and frontal neocortical regions. Magnetic resonance image studies of AD consistently reveal volumetric loss in the hippocampus using both cross-sectional and longitudinal approaches. The primary symptom of early-stage AD is memory impairment possibly accompanied by deficits in attentional control. Normal aging, however, is also marked by cognitive decline, as well as structural brain changes. Autopsy data had shown in the past that about 30% of older adults with no obvious cognitive impairment show some degree of the neuropathology typically associated with dementia at autopsy.
Importantly, the recent ability to image beta-amyloid and tau deposits in vivo using positron emission tomography (PET) scanning has revolutionized our understanding of early stages of AD. Evidence suggests that amyloid deposits may be detected 10 - 15 years before memory symptoms appear. These findings are leading to the ability to diagnose AD years before symptoms begin. Much less is known about the impact and developmental course of tau deposition as compared to beta-amyloid because the ligand to image tau was only recently invented. There is increasing evidence that tau is particularly toxic to the brain and is a later precursor of AD than amyloid deposits. Additional research on beta-amyloid and tau deposition in aging is crucial, as much work suggests that treatment of AD may be most effective when implemented early in the time course of the disease. Understanding the impact of tau deposits and its interactions with amyloid deposition allows the investigators to see the development of early markers of AD, which are important in understanding the trajectory of the disease. An important approach to understand the amyloid/tau puzzle and its relationship to AD is a large-scale longitudinal study of normal aging that integrates extensive neuroimaging and cognitive assessments along with tau imaging. A key aspect in understanding pathological aging is the need to be able to clearly differentiate normal aging from early pathology. The present Tau imaging study described here is an important component of the Dallas Lifetime Brain Study (DLBS).
The Dallas Lifespan Brain Study (DLBS) began in 2008 and was designed to utilize the new in vivo imaging techniques to address uncertainty regarding how AD pathology relates to the developmental process of aging and cognition, fueled in part by the partial overlap of pathological markers and decline in mnemonic function observed in a substantial proportion of 'normal' aged individuals. A total of 296 participants were recruited for Wave 1 from 2008 to 2014 to the DLBS and they received cognitive testing, structural and functional MRI, as well as a scan for beta amyloid using the radioligand AV-45 Florbetapir F 18 (also known as "\[18F\]AV-45"). A total of 183 returning participants were tested four years later in Wave 2, and they received the same battery as in Wave 1. In addition, 60 of these were also scanned with Flortaucipir F 18 (also known as "\[18F\]AV-1451"). \[18F\]AV-1451 is a newly-developed Phase II ligand that measures tau deposit in the human brain and this drug was provided to the DLBS by Avid Radiopharmaceuticals.
The objective of the current study is to test 125 DLBS participants with \[18F\]AV-1451 (Flortaucipir F 18) at the University of Texas Southwestern Medical Center (UTSW). The inclusion of tau imaging in Wave 3 will allow the investigators to relate tau deposition in the brain to the 10-year history of amyloid deposition and cognitive decline in the DLBS participants and understand the independent and joint contributions of tau to cognitive decline and early AD at different ages.
Importantly, the recent ability to image beta-amyloid and tau deposits in vivo using positron emission tomography (PET) scanning has revolutionized our understanding of early stages of AD. Evidence suggests that amyloid deposits may be detected 10 - 15 years before memory symptoms appear. These findings are leading to the ability to diagnose AD years before symptoms begin. Much less is known about the impact and developmental course of tau deposition as compared to beta-amyloid because the ligand to image tau was only recently invented. There is increasing evidence that tau is particularly toxic to the brain and is a later precursor of AD than amyloid deposits. Additional research on beta-amyloid and tau deposition in aging is crucial, as much work suggests that treatment of AD may be most effective when implemented early in the time course of the disease. Understanding the impact of tau deposits and its interactions with amyloid deposition allows the investigators to see the development of early markers of AD, which are important in understanding the trajectory of the disease. An important approach to understand the amyloid/tau puzzle and its relationship to AD is a large-scale longitudinal study of normal aging that integrates extensive neuroimaging and cognitive assessments along with tau imaging. A key aspect in understanding pathological aging is the need to be able to clearly differentiate normal aging from early pathology. The present Tau imaging study described here is an important component of the Dallas Lifetime Brain Study (DLBS).
The Dallas Lifespan Brain Study (DLBS) began in 2008 and was designed to utilize the new in vivo imaging techniques to address uncertainty regarding how AD pathology relates to the developmental process of aging and cognition, fueled in part by the partial overlap of pathological markers and decline in mnemonic function observed in a substantial proportion of 'normal' aged individuals. A total of 296 participants were recruited for Wave 1 from 2008 to 2014 to the DLBS and they received cognitive testing, structural and functional MRI, as well as a scan for beta amyloid using the radioligand AV-45 Florbetapir F 18 (also known as "\[18F\]AV-45"). A total of 183 returning participants were tested four years later in Wave 2, and they received the same battery as in Wave 1. In addition, 60 of these were also scanned with Flortaucipir F 18 (also known as "\[18F\]AV-1451"). \[18F\]AV-1451 is a newly-developed Phase II ligand that measures tau deposit in the human brain and this drug was provided to the DLBS by Avid Radiopharmaceuticals.
The objective of the current study is to test 125 DLBS participants with \[18F\]AV-1451 (Flortaucipir F 18) at the University of Texas Southwestern Medical Center (UTSW). The inclusion of tau imaging in Wave 3 will allow the investigators to relate tau deposition in the brain to the 10-year history of amyloid deposition and cognitive decline in the DLBS participants and understand the independent and joint contributions of tau to cognitive decline and early AD at different ages.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Alzheimer Disease
Cognitive Decline
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
DIAGNOSTIC
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Follow up DLBS participants
Eight to ten year follow-up DLBS participants who were cognitively normal at the time of enrollment from 2008 to 2014.
Group Type
EXPERIMENTAL
[18F]AV-1451
Intervention Type
DRUG
The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.
Positron Emission Tomography
Intervention Type
PROCEDURE
Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
[18F]AV-1451
The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.
Intervention Type
DRUG
Positron Emission Tomography
Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.
Intervention Type
PROCEDURE
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Flortaucipir F18
PET
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participated in Wave 1 or 2 of the DLBS study.
* Subjects must indicate that they are not currently pregnant if they are women of child-bearing potential. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: 1) Has not undergone a hysterectomy or bilateral oophorectomy; or 2) Has not been naturally post-menopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
* Volumetric Brain MRI Image (T-1 Weighted MPRage) collected as part of DLBS Wave 1, 2, or 3 protocol.
* Completed at least 9 years of formal education, or the equivalent of freshman year of high school.
* Fluent English speakers.
* Tolerate laying 20 minutes on a flat table for the PET scan.
* Ability to understand and the willingness to sign a written informed consent.
* Subjects must indicate that they are not currently pregnant if they are women of child-bearing potential. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: 1) Has not undergone a hysterectomy or bilateral oophorectomy; or 2) Has not been naturally post-menopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
* Volumetric Brain MRI Image (T-1 Weighted MPRage) collected as part of DLBS Wave 1, 2, or 3 protocol.
* Completed at least 9 years of formal education, or the equivalent of freshman year of high school.
* Fluent English speakers.
* Tolerate laying 20 minutes on a flat table for the PET scan.
* Ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria
* Mini-Mental State Examination (MMSE) score lower than 22; all DLBS participants at the time of initial Wave 1 enrollment between 2008 - 2014 had an MMSE score of 26 or above, indicating normal cognitive function. However, in the time interval between Wave 1 and Wave 3, it is possible that mental capacity may have deteriorated. The investigators will exclude all participants in Wave 3 testing who have an MMSE lower than 22.
* Taking some types of sedatives, benzodiazepines, or anti-psychotics.
* Currently undergoing chemotherapy or radiation for cancer.
* New history of substance abuse.
* Has a history of drug or alcohol dependence within the last year, or prior prolonged history of dependence.
* Recreational drug use in past six months.
* Central nervous systems disease or brain injury that would preclude participation in the study.
* Psychiatric or neurological disorder that would preclude participation in this study.
* Has clinically significant hepatic, renal, pulmonary, metabolic or endocrine disturbances which pose safety risk.
* Has a current clinically significant cardiovascular disease that poses a safety risk.
* Has a current clinically significant infectious disease or a medical comorbidity which poses a safety risk.
* Has either: 1) Screening electrocardiogram (ECG) with corrected QT Interval (QTc) \> 450 millisecond (msec) if male, or QTc \> 470 msec if female; or 2) A history of additional risk factors for Torsades de Pointes (TdP) (e.g., hypokalemia, family history of Long QT syndrome) or are taking drugs that are known to cause QT prolongation (a list of prohibited and discouraged medications is provided by the Sponsor); Patients with a prolonged QTc interval in the setting of intraventricular conduction block (examples right bundle branch block or left bundle branch block), may be enrolled with sponsor approval.
* Has received or will receive investigational medication within the 30 days of PET/CT scan.
* Has received or will receive a radiopharmaceutical for imaging or therapy within 24 hours of PET/CT scan.
* Is a participant who, in the opinion of the investigator(s), is otherwise unsuitable for a study of this type.
* Taking some types of sedatives, benzodiazepines, or anti-psychotics.
* Currently undergoing chemotherapy or radiation for cancer.
* New history of substance abuse.
* Has a history of drug or alcohol dependence within the last year, or prior prolonged history of dependence.
* Recreational drug use in past six months.
* Central nervous systems disease or brain injury that would preclude participation in the study.
* Psychiatric or neurological disorder that would preclude participation in this study.
* Has clinically significant hepatic, renal, pulmonary, metabolic or endocrine disturbances which pose safety risk.
* Has a current clinically significant cardiovascular disease that poses a safety risk.
* Has a current clinically significant infectious disease or a medical comorbidity which poses a safety risk.
* Has either: 1) Screening electrocardiogram (ECG) with corrected QT Interval (QTc) \> 450 millisecond (msec) if male, or QTc \> 470 msec if female; or 2) A history of additional risk factors for Torsades de Pointes (TdP) (e.g., hypokalemia, family history of Long QT syndrome) or are taking drugs that are known to cause QT prolongation (a list of prohibited and discouraged medications is provided by the Sponsor); Patients with a prolonged QTc interval in the setting of intraventricular conduction block (examples right bundle branch block or left bundle branch block), may be enrolled with sponsor approval.
* Has received or will receive investigational medication within the 30 days of PET/CT scan.
* Has received or will receive a radiopharmaceutical for imaging or therapy within 24 hours of PET/CT scan.
* Is a participant who, in the opinion of the investigator(s), is otherwise unsuitable for a study of this type.
Minimum Eligible Age
38 Years
Maximum Eligible Age
96 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neil M Rofsky, MD, MHA
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Neil M Rofsky, MD, MHA
Professor and Chair, Department of Radiology
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Denise Park, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Texas at Dallas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UT Southwestern Medical Center
Dallas, Texas, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Balota D.A., Faust M.E. (2001). Attention in dementia of the Alzheimer's type. In: Boller F, Cappa S, editors. Handbook of Neuropsychology. 2nd Ed. NY: Elsevier Science; pp. 51-80.
Reference Type
BACKGROUND
Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS. The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol. 2006 May;5(5):406-12. doi: 10.1016/S1474-4422(06)70417-3.
Reference Type
BACKGROUND
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-59. doi: 10.1007/BF00308809.
Reference Type
BACKGROUND
Convit A, de Leon MJ, Golomb J, George AE, Tarshish CY, Bobinski M, Tsui W, De Santi S, Wegiel J, Wisniewski H. Hippocampal atrophy in early Alzheimer's disease: anatomic specificity and validation. Psychiatr Q. 1993 Winter;64(4):371-87. doi: 10.1007/BF01064929.
Reference Type
BACKGROUND
Holm S: A Simple Sequentially Rejective Bonferroni Test. Scandinavian Journal of Statistics. 1979, 65 -670.
Reference Type
BACKGROUND
Kemper S, Anagnopoulos C, Lyons K, Heberlein W. Speech accommodations to dementia. J Gerontol. 1994 Sep;49(5):P223-9. doi: 10.1093/geronj/49.5.p223.
Reference Type
BACKGROUND
Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol. 1985 Nov;42(11):1097-105. doi: 10.1001/archneur.1985.04060100083029. No abstract available.
Reference Type
BACKGROUND
Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz F. Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol. 1993 Sep;50(9):949-54. doi: 10.1001/archneur.1993.00540090052010.
Reference Type
BACKGROUND
Jack, C., Knopman, D., Jagust, W., Petersen, R., Weiner, M., Aisen, P., … Trojanowski, J. (2013). Update on hypothetical model of Alzheimer's disease biomarkers. Alzheimer's & Dementia, 9(4), 521-522.
Reference Type
BACKGROUND
Jack CR Jr, Petersen RC, Xu YC, Waring SC, O'Brien PC, Tangalos EG, Smith GE, Ivnik RJ, Kokmen E. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997 Sep;49(3):786-94. doi: 10.1212/wnl.49.3.786.
Reference Type
BACKGROUND
Mohs RC, Ashman TA, Jantzen K, Albert M, Brandt J, Gordon B, Rasmusson X, Grossman M, Jacobs D, Stern Y. A study of the efficacy of a comprehensive memory enhancement program in healthy elderly persons. Psychiatry Res. 1998 Feb 27;77(3):183-95. doi: 10.1016/s0165-1781(98)00003-1.
Reference Type
BACKGROUND
Park DC, Reuter-Lorenz P. The adaptive brain: aging and neurocognitive scaffolding. Annu Rev Psychol. 2009;60:173-96. doi: 10.1146/annurev.psych.59.103006.093656.
Reference Type
BACKGROUND
Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol. 2001 Sep;58(9):1395-402. doi: 10.1001/archneur.58.9.1395.
Reference Type
BACKGROUND
Reuter-Lorenz PA, Park DC. How does it STAC up? Revisiting the scaffolding theory of aging and cognition. Neuropsychol Rev. 2014 Sep;24(3):355-70. doi: 10.1007/s11065-014-9270-9. Epub 2014 Aug 21.
Reference Type
BACKGROUND
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.
Reference Type
BACKGROUND
Storandt M, Grant EA, Miller JP, Morris JC. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology. 2002 Oct 8;59(7):1034-41. doi: 10.1212/wnl.59.7.1034.
Reference Type
BACKGROUND
Trojanowski JQ, Clark CM, Schmidt ML, Arnold SE, Lee VM. Strategies for improving the postmortem neuropathological diagnosis of Alzheimer's disease. Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S75-9. doi: 10.1016/s0197-4580(97)00075-4.
Reference Type
BACKGROUND
Whalley LJ. Brain ageing and dementia: what makes the difference? Br J Psychiatry. 2002 Nov;181:369-71. doi: 10.1192/bjp.181.5.369. No abstract available.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STU 092015-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
NCT05361382
ACTIVE_NOT_RECRUITING
PHASE1
Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination
NCT04305210
UNKNOWN
PHASE2
Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals
NCT00855868
COMPLETED
PHASE2
Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
NCT01202994
COMPLETED
PHASE2
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
NCT02016560
COMPLETED
PHASE2/PHASE3
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
NCT01028053
COMPLETED
PHASE3
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
NCT04079803
COMPLETED
PHASE2
Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers
NCT03902548
COMPLETED
PHASE1
Tau Screening Study in Subjects With Early Symptomatic AD
NCT03467477
COMPLETED
PHASE2
Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease
NCT03903211
COMPLETED
PHASE2
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
NCT04388254
COMPLETED
PHASE2
Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC
NCT00544453
TERMINATED
PHASE1
Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
NCT01265394
COMPLETED
PHASE3
Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients
NCT03435861
COMPLETED
PHASE2
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
NCT00857415
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
NCT03289143
TERMINATED
PHASE2
R21 Roche: 3-Way Tau Tracers in AD
NCT05464368
RECRUITING
PHASE1
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
NCT02423122
COMPLETED
PHASE2
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
NCT01492374
COMPLETED
PHASE1
A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease
NCT00988598
COMPLETED
PHASE1
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
NCT04994483
COMPLETED
PHASE3
APOE in the Predisposition to, Protection From, and Prevention of Alzheimer's Disease
NCT04994847
ENROLLING_BY_INVITATION
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
NCT01227564
COMPLETED
PHASE2
A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease
NCT00930059
COMPLETED
PHASE2
Ultralow Dose PET Imaging of 18F-Florbetapir, 18F-Flutemetamol
NCT07012993
RECRUITING
PHASE2